Food and Drug Administration

Oncologic Drugs Advisory Committee

June 2, 2006

Briefing Information

Bristol-Myers Squibb Company
The statements contained in this document(s) are those of the product’s sponsor, not
FDA, and FDA does not necessarily agree with the sponsor’s statements. FDA has not
made a final determination about the safety or effectiveness of the product described in
this document.

Bristol-Myers Squibb Briefing Material for Sprycel

FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the
Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
These redacted portions will appear as white space on the screen or on the printed page.

FDA Briefing Material for Sprycel

---